Isoprinosine increases the antitumor action of interferon.
The association of relatively low doses of interferon with an immunostimulant (isoprinosine) enhances the antitumor effect of interferon. After combined treatment, the mean survival time, tumor incidence, and final survival rate are significantly increased in mice inoculated with 10(6) Crocker tumor 180/TG cells when compared to mice treated with interferon alone.
D000818:Animals; D004357:Drug Synergism; D004359:Drug Therapy, Combination; D007288:Inosine / Q000031:analogs & derivatives*; D007542:Inosine Pranobex / Q000008:administration & dosage*; D007372:Interferons / Q000008:administration & dosage*; D008297:Male; D051379:Mice; D012510:Sarcoma 180 / Q000188:drug therapy*; D013997:Time Factors
D007288:Inosine; D007372:Interferons; D007542:Inosine Pranobex